Each year, more than one million planned surgeries in EU and US result in blood transfusion, reoperation or fatality due to uncontrolled bleeding in the hospital. No single dressing can effectively control severe arterial or venous bleedings. This project will develop a new class of general hemostatic dressings for surgical applications in hospitals for controlling bleedings. It will be the first treatment of bleeding, which uses Tissue Factor (TF), the endogenous initiator and accelerator of the extrinsic coagulation path responsible for hemostasis. Previously, we have demonstrated that the binding of recombinant extracellular TF permanently to a dressing using a chemical linker efficiently stops severe carotid artery bleedings in minipigs, outperforming competing systems. Also, we have shown that the active TF protein in our system is permanently bound, is stable over time and safe. In this project, we will develop a novel manufacturing technology, which can convert any general dressing system used in planned surgery – gauze, swaps, sponges, etc. - to become highly hemostatic in one simple high-yield manufacturing processing step. The new hemostatic dressing systems will be tested in a pre-clinical laparoscopic ovary and in a spleen bleeding model, to illustrate the utility of the technology in some of the most challenging surgical applications.